In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet
Publication
, Journal Article
Armstrong, AJ
Published in: Oncology (Williston Park, N.Y.)
October 1, 2014
Duke Scholars
Published In
Oncology (Williston Park, N.Y.)
ISSN
0890-9091
Publication Date
October 1, 2014
Volume
28
Issue
10
Start / End Page
883
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J. (2014). In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park, N.Y.), 28(10), 883.
Armstrong, A. J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park, N.Y.) 28, no. 10 (October 1, 2014): 883.
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park, NY). 2014 Oct 1;28(10):883.
Armstrong, A. J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park, N.Y.), vol. 28, no. 10, Oct. 2014, p. 883.
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park, NY). 2014 Oct 1;28(10):883.
Published In
Oncology (Williston Park, N.Y.)
ISSN
0890-9091
Publication Date
October 1, 2014
Volume
28
Issue
10
Start / End Page
883